Pregnancy: Pregnancy Category B. For Ceftriaxone/Sulbactam 1.5 g/Vial Powder for Solution for Injection/Infusion, limited clinical data on Elores exposed pregnancies are available. Ceftriaxone crosses the placental barrier. Reproductive studies in animals have shown no evidence of embryotoxicity, foetotoxicity, teratogenicity or adverse effects on male or female fertility, birth or perinatal and postnatal development. In primates, no embryotoxicity or teratogenicity has been observed. Since safety in human pregnancy is not established, Elores should be used with caution.
Lactating women/Nursing mother: Low concentrations of ceftriaxone and sulbactam are excreted in the milk; therefore, caution should be exercised when ELORES is administered to a nursing woman.